AstraZeneca is committed to discovering and developing compounds that improve patient care in neuroscience.

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. 

 

Our focus on unmet medical needs

More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.

  • Alzheimer's disease (AD)

    AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.


  • Opioid-induced constipation (OIC)

    OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.


What we're working on

We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

        Image: Artistic rendering of BACE enzyme.

Collaboration stories

Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers


Opportunities for collaboration

Our approach in Neuroscience looks to maximise revenue through externalisation and on-market products; advance the novel product pipeline with partnerships where appropriate; and preserve a company stake in the most promising assets.


Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Our medicines

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

  • Diprivan propofol
  • EMLA EMLA
  • Movantik/Moventig naloxegol
  • Naropin ropivacaine
  • Seroquel IR quetiapine fumarate
  • Seroquel XR quetiapine fumarate
  • Xylocaine lidocaine
  • Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon zolmitriptan

Resources




Veeva ID: Z4-3582
Date of next review: March 2018